Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly's Zepbound Challenges Novo Nordisk's Wegovy Amid Supply Issues
Eli Lilly And Company's (NYSE:LLY) weight-loss drug, Zepbound (tirzepatide), is gaining traction in the U.S., rivaling Novo Nordisk A/S's (NYSE:NVO) Wegovy (semaglutide).
伊利莎白·利利公司（NYSE:LLY）的減肥藥Zepbound（地塞帕肽）在美國越來越受歡迎，與諾和諾德A/S（NYSE:NVO）的Wegovy（塞格列汀）相媲美。
Due to ongoing supply issues, some doctors are prioritizing availability when prescribing these medications.
由於持續供應問題，一些醫生在開處方藥時會優先考慮藥物的可用性。
Also Read: Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks.
此外，使用Wegovy、Zepbound等減肥藥物的心理學家警告存在與進食障礙風險相關的問題。
Reuters noted, citing IQVIA data, that Eli Lilly has captured roughly 40% of the market since Zepbound's December launch.
據IQVIA數據稱，自Zepbound在12月上市以來，伊利莎白·利利公司已經佔據了約40%的市場。
As of July 19, 130,000 prescriptions were filled weekly, compared to 200,000 for Wegovy.
截至7月19日，每週約填寫130,000份處方，而Wegovy爲200,000份。
Five U.S. obesity specialists revealed they prescribe whichever drug is more accessible, sometimes requiring patients to switch treatments to maintain continuity.
五位美國肥胖症專家透露，他們會開具更容易拿到的藥物，有時需要患者更換藥物以保持療效。
Investors are keenly awaiting updates from Novo Nordisk and Lilly during their quarterly earnings release this week.
投資者將密切關注諾和諾德和利蓮公司在本週季度財務會議的更新。
"All doses of Mounjaro and Zepbound are listed as available on the FDA's website, consistent with our previous statements that supply would steadily improve toward the latter half of 2024," Reuters added, quoting an Eli Lilly spokesperson.
路透社援引伊利莎白·利利公司的發言人表示："Mounjaro和Zepbound的所有劑量均已列入FDA網站，這與我們之前的聲明一致，即供應將穩步提高，直至2024年下半年。"
"While we will do our best to support those who want to start taking Wegovy, it is important to recognize that overall demand will continue to exceed supply, and some patients may still have difficulty filling Wegovy prescriptions," Novo Nordisk noted in an update on its website.
諾和諾德在其網站上更新說："儘管我們會盡最大努力支持那些想開始使用Wegovy的患者，但有必要認識到總體需求仍將超過供應，一些患者可能仍難以獲得Wegovy處方。"
Meanwhile, Lilly's CEO recently assured that the Zepbound shortage would be resolved "very soon." The FDA updated its status on Friday, indicating that while Zepbound is available, it remains on the shortage list pending confirmation of stable supplies.
與此同時，利蓮公司的CEO最近保證，Zepbound的藥短缺問題將"很快"解決。FDA上週五更新了其狀態，說明雖然Zepbound可用，但其仍在短缺清單上，需要確認穩定的供應。
The FDA's website still lists shortages for the lowest three out of five dose strengths of Wegovy. Since Q2, Novo Nordisk has averaged nearly 170,000 weekly U.S. prescriptions for Wegovy, while Lilly has filled just under 100,000.
FDA網站仍然列出Wegovy五個劑型中最低的三個劑量存在短缺。自第二季度以來，諾和諾德在美國的Wegovy處方量平均每週近170,000張，而利蓮公司僅填寫了將近100,000張。
Analysts predict a roughly even market split by the end of 2024 as Lilly boosts its manufacturing capacity.
分析師預計到2024年底，市場份額將基本相當，因爲利蓮公司將增加其製造能力。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases.
- FDA小組支持Zevra的Arimoclomol治療罕見遺傳性疾病，分析師強調其平衡的市場產品組合和側重於罕見疾病的管道資產。
Photo by Ciara Kimsey via Shutterstock
照片來自Shutterstock